12:00 AM
 | 
May 02, 2005
 |  BioCentury  |  Finance

EPS watch

EPS watch

Company 1Q05 EPS est 1Q05 EPS actual Outcome Growth from 1Q04 4/29 cls Wk chg % chg Mcap chg 4/29 Mcap
Applied Biosystems (ABI) (A) $0.25 $0.28 Beat by $0.03 33% $21.20 $1.14 6% $223.9 $4,164.0
3Q05 revenues were up 4% to $455M from $439.6M in 3Q04.
AstraZeneca (LSE:AZN; AZN) $0.58 $0.63 Beat by $0.05 33% $43.95 $0.68 2% $1,115.2 $72,078.0
1Q05 sales were up 9% to $5.7B from $5.1B in 1Q04. Sales of cholesterol drug Crestor were up 106% to $273M. AZN said sales of cancer drug Iressa have fallen 41% since it stopped promoting the EGFr inhibitor because of a failed Phase III trial in December 2004. 1Q05 Iressa sales were $81M.
Bayer (FSE:BAYG; BAY) NA E0.89 NA 56% $32.25 $0.65...

Read the full 826 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >